Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Johnson & Johnson (JNJ) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 302,795,264
  • Shares Outstanding, K 2,735,880
  • Annual Sales, $ 70,074 M
  • Annual Income, $ 15,409 M
  • 36-Month Beta 0.72
  • Price/Sales 4.32
  • Price/Book 4.19

Price Performance

See More
Period Period Low Period High Performance
1-Month
111.00 +0.86%
on 12/01/16
122.50 -8.60%
on 11/09/16
-2.90 (-2.52%)
since 11/02/16
3-Month
111.00 +0.86%
on 12/01/16
122.50 -8.60%
on 11/09/16
-7.36 (-6.17%)
since 09/02/16
52-Week
94.28 +18.75%
on 01/21/16
126.07 -11.19%
on 07/20/16
+9.91 (+9.71%)
since 12/02/15

Most Recent Stories

More News
MedTech Sails Through Macro Woes: Stocks in Focus

MedTech Sails Through Macro Woes: Stocks in Focus

Funding For Lawsuits Extends Pinnacle Hip Lawsuit Funding

Funding for Lawsuits (www.fundingforlawsuits.com), LLC, the nation's fastest growing pre settlement funding firm, announces today that they are extending their Pinnacle Hip Lawsuit Funding program to qualified...

Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Roche

Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Roche

Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytruda

This week, companies like Merck (MRK) and Pfizer (PFE) provided updates on their pipelines.

Dallas Jury Returns $1 Billion-Plus Verdict in Defective DePuy Hip Implants Lawsuit

A federal jury in Dallas has returned a combined verdict of more than $1 billion on behalf of six people who suffered serious medical complications caused by defective metal-on-metal hip implants made...

MedTech Industry Stock Outlook - December 2016

MedTech Industry Stock Outlook - December 2016

Achillion, J&J to Initiate Phase IIb Study on HCV Combo

Achillion Pharmaceuticals, Inc. (ACHN) announced the initiation of patient dosing in a global phase IIb on JNJ-4178 ??? a triple combination of AL-335, odalasvir (also known as ACH-3102) and J&J's Olysio...

Pfizer's Herceptin Biosimilar Meets Primary Endpoint in Study

Pfizer, Inc. (PFE) recently announced that its experimental biosimilar of Roche Holding AG's (RHHBY) breast cancer drug - Herceptin - has reached the primary endpoint in a pivotal study.

J&J (JNJ) Stands Tall in 2016: Reasons for Outperformance

Johnson & Johnson's (JNJ) share price is up 9.5% in the year-to-date period. This compares favorably with the 8.0% fall for the Zacks classified Large-Cap Pharma industry.

Achillion Announces Initiation of Patient Dosing by Janssen in a Global, Short Treatment-Duration Phase 2b Study of JNJ-4178 in Chronic HCV

- Janssen initiates dosing of patients in OMEGA-1: Phase 2b study evaluating six- and eight-week treatment durations with JNJ-4178, a 3DAA combination of odalasvir, simeprevir, and AL-335, for the treatment...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Support & Resistance

2nd Resistance Point 113.07
1st Resistance Point 112.51
Last Price 111.96
1st Support Level 111.42
2nd Support Level 110.89

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.